Eurand to Present At UBS Global Specialty and Generic Pharmaceuticals Conference

Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and biopharmaceutical
products based on its proprietary drug formulation technologies, announced today
that it is scheduled to present at the upcoming UBS Global Specialty and Generic
Pharmaceuticals Conference in London, England on Wednesday, May 28, 2008.
Gearoid Faherty, Chief Executive Officer of Eurand, will be presenting.

Event: UBS Global Specialty and Generic Pharmaceuticals Conference
Date: Wednesday, May 28, 2008
Time: 4:30 p.m. BST (11:30 a.m. EDT)
Place: The Waldorf Hilton
Aldwych
London WC2B 4DD
An audio webcast of the Company's presentation will be available by accessing
the investor relations section of Eurand's website at http://www.eurand.com. A
replay of the presentation will be available through June 28, 2008.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and
commercializes enhanced pharmaceutical and biopharmaceutical products based on
its proprietary drug formulation technologies. Eurand has had four partnered
products approved by the FDA since 2001 and has a pipeline of product candidates
in development for itself and its collaboration partners. Eurand has completed
two phase III clinical trials on its lead product candidate, EUR-1008 (Zentase),
intended for the treatment of pancreatic insufficiency and has submitted an NDA
for this product. Eurand's technology platforms include bioavailability
enhancement of poorly soluble drugs, customized release,
taste-masking/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For more
information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to information contained in
this release, constitutes forward-looking statements. Such forward-looking
statements include those which express plan, anticipation, intent, contingency,
goals, targets or future development and/or otherwise are not statements of
historical fact including, but not limited to the status of our NDA filing and
the plans for MAA filing relating to EUR-1008, enrollment and future plans for
our clinical trials, progress of and reports of results from clinical studies,
clinical development plans and product development activities. The words
"potentially," "could," "calls for" and similar expressions also identify
forward-looking statements. These statements are based upon management's current
expectations and are subject to risks and uncertainties, known and unknown,
which could cause actual results and developments to differ materially from
those expressed or implied in such statements. Factors that could affect actual
results include risks associated with the possibility that the FDA does not
approve our NDA or delays approval; the outcome of any discussions with the FDA;
and unexpected delays in preparation of materials for submission to the FDA as a
part of our NDA filing. Forward-looking statements contained in this press
release are made as of this date, and we undertake no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise. Actual events could differ materially from those
anticipated in the forward-looking statements.

-0-
CONTACT: Eurand N.V.
Mario Crovetto, Chief Financial Officer
+39 02 95428 521
mario.crovetto@eurand.com

The Ruth Group
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com
Sara Ephraim
646-536-7002
sephraim@theruthgroup.com